The single nucleotide variant **rs121913279** is associated with a pathogenic mutation in the **TP53** gene, which encodes the tumor suppressor protein p53. This variant is specifically a missense mutation, often referred to as **R175H** (arginine at position 175 is replaced by histidine). It is one of the most well-studied mutations in TP53 and is implicated in various cancers, including breast, lung, and ovarian cancers.

### Molecular Mechanisms Affected:
1. **Loss of Tumor Suppressor Function**:
   - The p53 protein normally acts as a transcription factor that regulates genes involved in cell cycle arrest, DNA repair, and apoptosis. The R175H mutation disrupts the DNA-binding domain of p53, impairing its ability to bind to target gene promoters and activate transcription. This leads to a loss of tumor suppressor activity.

2. **Dominant-Negative Effect**:
   - The mutant p53 protein can form tetramers with wild-type p53, inhibiting the function of the remaining normal p53 protein. This dominant-negative effect further compromises the tumor-suppressive functions of p53.

3. **Gain of Function (GOF)**:
   - In addition to losing its normal function, the R175H mutant p53 protein can acquire new oncogenic properties. These include promoting cell proliferation, invasion, and metastasis, as well as resistance to chemotherapy and radiation therapy.

4. **Impaired DNA Damage Response**:
   - Wild-type p53 is activated in response to DNA damage and induces cell cycle arrest or apoptosis. The R175H mutation prevents this activation, allowing cells with damaged DNA to continue dividing, which contributes to genomic instability and cancer progression.

5. **Altered Interaction with Other Proteins**:
   - The R175H mutant p53 protein can interact abnormally with other cellular proteins, such as p63 and p73, which are members of the p53 family. This disrupts their normal tumor-suppressive functions and further promotes oncogenesis.

---

### 分子メカニズムにおける影響:
1. **腫瘍抑制機能の喪失**:
   - p53タンパク質は通常、細胞周期停止、DNA修復、アポトーシスに関与する遺伝子を調節する転写因子として機能します。R175H変異はp53のDNA結合ドメインを損傷し、標的遺伝子プロモーターへの結合と転写活性化を妨げます。その結果、腫瘍抑制機能が失われます。

2. **優性陰性効果 (Dominant-Negative Effect)**:
   - 変異型p53タンパク質は、野生型p53と四量体を形成し、残存する正常なp53タンパク質の機能を阻害します。この優性陰性効果により、p53の腫瘍抑制機能がさらに損なわれます。

3. **機能獲得 (GOF)**:
   - R175H変異型p53タンパク質は、新たな発がん性の特性を獲得することがあります。これには、細胞増殖、浸潤、転移の促進や、化学療法や放射線療法への耐性が含まれます。

4. **DNA損傷応答の障害**:
   - 野生型p53はDNA損傷に応答して活性化され、細胞周期停止やアポトーシスを誘導します。R175H変異はこの活性化を妨げ、損傷したDNAを持つ細胞が分裂を続けることを可能にし、ゲノム不安定性と癌の進行に寄与します。

5. **他のタンパク質との相互作用の変化**:
   - R175H変異型p53タンパク質は、p63やp73などのp53ファミリーのメンバーと異常に相互作用することがあります。これにより、それらの正常な腫瘍抑制機能が妨げられ、発がんがさらに促進されます。

This mutation is a critical target for cancer research and therapeutic development due to its significant role in tumorigenesis.  
この変異は腫瘍形成における重要な役割を果たすため、癌研究や治療法開発の重要なターゲットとなっています。